Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?

被引：47

作者：

Abou-Alfa, G. K.

Amadori, D.

Santoro, A.

Figer, A.

De Greve, J.

Lathia, C.

Voliotis, D.

Anderson, S.

Moscovici, M.

Ricci, S.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Osped Morgagni Pierantoni, Forli, Italy

[3] Ist Clin Humanitas, Rozzano, Italy

[4] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[5] UZ Brussel VUB, Brussels, Belgium

[6] Bayer Pharmaceut Corp, Wayne, NJ USA

[7] Bayer Schering Pharma, Wuppertal, Germany

[8] Bayer SpA PH, Milan, Italy

[9] Osped S Chiara, Pisa, Italy

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.4518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4518

引用

页数：1